Market Indices


Latest News

Jefferies analyst issues BUY recommendation for DNTH on March 9,...

March 9, 2026   DNTH 20.94%

Rodman & Renshaw analyst issues BUY recommendation for KPTI on...

March 9, 2026   KPTI -3.31%

Rodman & Renshaw analyst issues BUY recommendation for ELTX on...

March 9, 2026   ELTX 0.52%

Oppenheimer analyst issues OUTPERFORM recommendation for TRVI on March 9,...

March 9, 2026   TRVI -10.86%

Oppenheimer analyst issues OUTPERFORM recommendation for ABEO on March 9,...

March 9, 2026   ABEO 6.98%


Price Targets

Trevor Allred from Oppenheimer issued a price target of $145.00 for DNTH on 2026-03-09 14:15:00.The adjusted price target was set to $145.00.At the time of the announcement, DNTH...

March 9, 2026   DNTH 20.94%

Alex Thompson from Stifel Nicolaus issued a price target of $120.00 for DNTH on 2026-03-09 14:14:00.The adjusted price target was set to $120.00.At the time of the announcement,

March 9, 2026   DNTH 20.94%

Michael Shlisky from D.A. Davidson issued a price target of $23.00 for MEC on 2026-03-09 12:41:00.The adjusted price target was set to $23.00.At the time of the announcement,

March 9, 2026   MEC -1.36%

Andrew Tsai from Jefferies issued a price target of $10.00 for ATAI on 2026-03-06 20:37:00.The adjusted price target was set to $10.00.At the time of the announcement, ATAI...

March 6, 2026   ATAI 13.72%

Brian Holland from D.A. Davidson issued a price target of $24.00 for MAMA on 2026-03-06 13:50:00.The adjusted price target was set to $24.00.At the time of the announcement,

March 6, 2026   MAMA -0.96%



Market Movers

Top Gainers (%)
EGRX
Eagle Pharmaceuticals, In
0.34
127.40%
ATRA
Atara Biotherapeutics, In
6.76
30.75%
DNTH
Dianthus Therapeutics, In
78.85
20.94%
TMCWW
TMC the metals company In
0.86
20.49%
AXTI
AXT, Inc.
38.50
18.92%
BTAI
BioXcel Therapeutics, Inc
1.76
18.92%
CCCC
C4 Therapeutics, Inc.
3.57
17.27%
SLDB
Solid Biosciences Inc.
7.92
17.26%

Annual/Quarterly Reports Summary

In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...

November 6, 2024   AIP -0.45%

In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...

November 6, 2024   EOSEW -34.96%

In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...

November 6, 2024   EOSE -0.16%

In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...

November 5, 2024   STOK 7.81%

In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...

November 5, 2024   BSVN -3.48%